![]() | "Descrizione" by admin (19547 pt) | 2025-Jan-04 18:39 |
PURITE® è un conservante registrato e proprietario, ampiamente utilizzato in applicazioni mediche e cosmetiche. Questa soluzione stabilizzata di complessi ossiclorati è riconosciuta per le sue proprietà antimicrobiche ad ampio spettro, che la rendono efficace nel prevenire la contaminazione e nel preservare l'integrità delle formulazioni. Grazie al suo profilo di sicurezza e alla sua efficacia, PURITE® è particolarmente adatto per applicazioni sensibili, come soluzioni oftalmiche e prodotti per la cura personale.
PURITE® è un complesso ossiclorato stabilizzato (SOC) composto da diossido di cloro, cloriti e clorati.
Componenti principali:
Proprietà:
Sintesi:
Stabilizzazione:
Controllo qualità:
Conservante:
Formulazioni delicate:
Clean Beauty:
Biodegradabilità:
Profilo di sicurezza:
Sostenibilità:
PURITE® è una soluzione conservante avanzata che offre protezione antimicrobica ad ampio spettro con un profilo di sicurezza delicato. La sua capacità di decomporsi in sottoprodotti ecologicamente sicuri, unita alla sua idoneità per applicazioni sensibili, lo rende una scelta preziosa per formulazioni oftalmiche, cosmetiche e per la cura personale.
Bibliografia__________________________________________________________________________
Messmer EM. Preservatives in ophthalmology. Ophthalmologe. 2012 Nov;109(11):1064-70.
Abstract. Preservatives are a legal requirement for eye drops in multidose containers. Moreover, they are necessary for stabilization and intraocular penetration for a number of ophthalmic preparations. Most preservatives act in a relatively unspecific manner as detergents or by oxidative mechanisms and thereby cause side effects at the ocular surface. They may also affect the lens, trabecular meshwork and the retina. Benzalkonium chloride is the most commonly used preservative in ophthalmology and is more toxic than other or newer preservatives, such as polyquaternium-1 (Polyquad), sodium perborate, oxychloro-complex (Purite®) and SofZia. Preservative-free topical medication is highly recommended for patients with ocular surface disease, frequent eye drop administration, proven allergy to preservatives and contact lens wear.
Kahook MY, Rapuano CJ, Messmer EM, Radcliffe NM, Galor A, Baudouin C. Preservatives and ocular surface disease: A review. Ocul Surf. 2024 Oct;34:213-224. doi: 10.1016/j.jtos.2024.08.001.
Abstract. Ocular surface disease (OSD) is a complex condition that can cause a range of symptoms (e.g, dryness, irritation, and pain) and can significantly impact the quality of life of affected individuals. Iatrogenic OSD, a common finding in patients with glaucoma who receive chronic therapy with topical ocular antihypertensive drugs containing preservatives such as benzalkonium chloride (BAK), has been linked to damage to the ocular surface barrier, corneal epithelial cells, nerves, conjunctival goblet cells, and trabecular meshwork. Chronic BAK exposure activates inflammatory pathways and worsens symptoms, compromising the success of subsequent filtration surgery in an exposure-dependent manner. In eyes being treated for glaucoma, symptomatic treatment of OSD may provide some relief, but addressing the root cause of the OSD often necessitates reducing or, ideally, eliminating BAK toxicity. Strategies to decrease BAK exposure in patients with glaucoma encompass the use of preservative-free formulations or drugs with alternative and less toxic preservatives such as SofZia®, Polyquad, potassium sorbate, or Purite®. Though the benefits of these alternative preservatives are largely unproven, they might be considered when financial constraints prevent the use of preservative-free versions. For patients receiving multiple topical preserved drugs, the best practice is to switch to nonpreserved equivalents wherever feasible, regardless of OSD severity. Furthermore, nonpharmacological approaches, including laser or incisional procedures, should be considered. This review explores the effects of BAK on the ocular surface and reviews strategies for minimizing or eliminating BAK exposure in patients with glaucoma in order to significantly improve their quality of life and prevent complications associated with chronic exposure to BAK. Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Evaluate |